GSK PLC closed 14.69% below its 52-week high of £17.67, which the company reached on May 31st.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...

Stocks of several companies, including Advani Hotels & Resorts (India), Bajaj Finance, GlaxoSmithKline Pharmaceuticals, ...

According to data from the BSE, Angel One has declared a final dividend of ₹26 per share, Bajaj Finance ₹44 per share, and ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we have what it ...

"Complicated UTIs can have a profound impact on patients and carry a high risk of clinical complications, including sepsis and septic shock," said GSK Chief Scientific Officer Tony Wood. "These ...

GSK PLC closed 18.99% short of its 52-week high of £17.88, which the company achieved on May 28th.

Companies including Angel One, Bajaj Finance, ITC, Tata Consumer Products, L&T Finance, Infosys and Colgate Palmolive (India) ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...